Drug Search Results
More Filters [+]

GEN-1056

Alternative Names: GEN-1056, GEN 1056, GEN1056, BNT322, BNT-322, BNT 322
Latest Update: 2024-05-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Genmab
Company Location: 1253 COPENHAGEN K G7 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GEN-1056

Countries in Clinic: Georgia, Moldova, Spain

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Central Nervous System Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GCT1056-01

P1

Active, not recruiting

Central Nervous System Cancer

2025-12-18

Recent News Events

Date

Type

Title